Table 1.
Clinical and hemodynamic characteristics of STEMI patients, stable CAD, and healthy volunteers.
| Healthy volunteers (n = 10) | Stable CAD (n = 10) |
STEMI (n = 15) |
|
|---|---|---|---|
| Age, years, mean (SEM) | 61 (3·4) | 67 (2·2)* | 59 (2·8) |
| Female, n (%) | 2 (20) | 4 (60) | 2 (13) |
| Body mass index, kg/m2, mean (SEM) | 24·5 (0·6) | 31·0 (1·7)** | 26·2 (0·7) |
| Blood pressure, systolic, mmHg, mean (SEM) | 125 (5·4) | 154 (4·0)* | 131 (8·2) |
| Blood pressure, diastolic, mmHg, mean (SEM) | 80 (3·4) | 80 (2·8) | 79 (3·6) |
| Symptom onset to inclusion, hours, mean (min, max) | – | – | 2·6 (0·9, 4·7) |
| Maximum hsTnT, ng/L, mean (min, max) | – | – | 2681 (1096, 9557) |
| GRACE score, mean (SEM) | – | – | 105 (6·0) |
| Multi vessel disease, n (%) | 0 | 4 (40) | 7 (47) |
| History | |||
| Diabetes mellitus, n (%) | 0 | 2 (20) | 0 |
| Current smoking, n (%) | 0 | 0 | 8 (53) |
| Previous myocardial infarction, n (%) | 0 | 1 (10) | 1 (7) |
| Medication on admittance | |||
| Aspirin, n (%) | 0 | 10 (100) | 15 (100) |
| Clopidogrel, n (%) | 0 | 1 (6·3) | 15 (100) |
| Ticagrelor, n (%) | 0 | 0 | 0 |
| Prasugrel, n (%) | 0 | 0 | 0 |
| Low molecular weight heparin, n (%) | 0 | 0 | 15 (100) |
| Statin, n (%) | 0 | 9 (90) | 3 (20) |
Data given as mean (SEM) or number of subjects (%). hsTnT, high-sensitivity Troponin T. *p < 0·05, **p < 0·01 vs. STEMI baseline